Swallowed capsule can identify health problems from inside the gut and send alert

Scientists have developed a swallowed capsule packed with tiny electronics and millions of genetically engineered living cells that might someday be used to spot health problems from inside the gut. The capsule was tested in pigs and correctly detected signs of bleeding researchers at the Massachusetts Institute of Technology report in the journal Science, suggesting the capsule could eventually be used in people to find signs of ulcers, inflammatory bowel disease or even colon cancer.

American Cancer Society updates colorectal cancer screening guidelines

The American Cancer Society (ACS) has released an updated guideline for colorectal cancer screening. Among the major guideline changes, the new recommendations state screening should begin at age 45 for people at average risk. Previously, the guideline recommended screening begin at age 50 for people at average risk.  The recommendations for screening test options are also part of the guideline changes.

Soy lecithin NSAID combination protects against cancer

Scientists at The University of Texas Health Science Center at Houston (UTHealth) have applied a chemical found in soybeans to non-steroidal anti-inflammatory drug (NSAID) and increased its anticancer properties and reduced its side effects. Findings of the preclinical study of phosphatidylcholine (also called lecithin), 'Chemoprevention with phosphatidycholine non-steroidal anti-inflammatory drugs in vivo and in vitro', was published in Oncology Letters. 

Blue dye tablet helps identify polyps during colonoscopy

Ingestion of a blue dye tablet during bowel prep for colonoscopy could be a significant advance in the early detection of colorectal cancer (CRC), according to research to be presented at Digestive Disease Week (DDW) 2018. Study researchers from Humanitas University Medical School in Milan, Italy, found that when used in conjunction with colonoscopy, the blue dye increased adenoma detection rate (ADR) by nearly 9 percent.

Vaccine treatment for colorectal cancer to undergo first human study

For the first time in humans, researchers will test a two-pronged approach to treat advanced stage colorectal cancer (CRC), potentially increasing life expectancy. Combining a DNA vaccine, which boosts the body's immune response against tumours, with an antibody that blocks the body's natural defence against the potency of the DNA vaccine, may lead to the development of an effective treatment for late stage CRC, when a cure is not often possible. Preliminary research leading up to this trial will be presented at Digestive Disease Week 2018 in June.

Surveillance intensity not associated with improved survival in colorectal cancer

A US retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.

Casting light to remedy debilitating gastrointestinal conditions

A novel light therapy is being investigated as an alternative to prescription drugs to relieve chronic constipation and other intestinal disorders which affect millions of patients around the world. Researchers at Flinders University and Washington University have found a "significant technical breakthrough" in a new light and optogenetics technique which has the potential to replace drugs as a less toxic remedy to debilitating gastrointestinal conditions.